$3.48
1.61% today
Nasdaq, Dec 30, 09:47 pm CET
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

scPharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
about 2 months ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwrigh...
Neutral
GlobeNewsWire
about 2 months ago
Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company throu...
Neutral
GlobeNewsWire
about 2 months ago
Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET
Neutral
GlobeNewsWire
3 months ago
Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease
Neutral
Seeking Alpha
5 months ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earni...
Neutral
GlobeNewsWire
5 months ago
Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today...
Neutral
GlobeNewsWire
5 months ago
BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at ...
Neutral
GlobeNewsWire
5 months ago
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today